Xcout IntelAmneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Subscribe to see Amneal Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amneal Pharmaceuticals, Inc. at a glance
Amneal Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Bridgewater, United States. It is publicly listed (AMRX) with a market capitalisation of $6.4B. Xcout tracks 26 named people at Amneal Pharmaceuticals, Inc., including Anastasios G. Konidaris (Executive Vice President & Chief Financial Officer). Xcout recorded 107 job postings from Amneal Pharmaceuticals, Inc. in the last 90 days.
Amneal Pharmaceuticals, Inc. leadership
- Anastasios G. KonidarisExecutive Vice President & Chief Financial Officer
- Andrew S. BoyerExecutive Vice President and Chief Commercial Officer of Generics & Biosciences
- Jason DalyExecutive Vice President, Chief Legal Officer & Corporate Secretary
- Nikita ShahExecutive Vice President & Chief Human Resources Officer
- Sanjay Kumar JainChief Quality Officer
- Chintu PatelCo-Founder, Co-CEO & Director
20 more named people on record for Amneal Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Amneal Pharmaceuticals, Inc.
Xcout recorded 107 job postings from Amneal Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Amneal Pharmaceuticals, Inc.'s hiring signals →
Recent Amneal Pharmaceuticals, Inc. news
- AcquisitionMerger proxy (DEFM14A)
3 corporate events on record, with sources — see the full timeline →
Amneal Pharmaceuticals, Inc. competitors
A few of Amneal Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing, and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis operates in approximately 100 countries and has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey.
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
Viatris is a global healthcare company that develops, manufactures, and supplies a wide range of pharmaceutical products, including generics, established brands, and innovative medicines. The company serves patients worldwide across various therapeutic areas to address significant unmet medical needs.
Akorn, Inc. is a pharmaceutical company with its main headquarters located in Lake Forest, Illinois, alongside various manufacturing and operational facilities.
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
SK-Pharma is a global pharmaceutical company and supplier of medications, specializing in early generics, rare drugs, value-added generics, and specialty products such as orphan drugs and complex generics. The company focuses on improving drug accessibility, market monitoring, and supply chain optimization to serve patients worldwide.
Get Amneal Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amneal Pharmaceuticals, Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access